| Basics |
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company dedicated to the development of pharmaceutical products to address public health challenges. Its drug development program is focused on delivering treatment for PTSD.
|
| IPO Date: |
June 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$172.69M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 4.46%
|
| Avg Daily Range (30 D): |
$0.80 | 3.21%
|
| Avg Daily Range (90 D): |
$1.64 | 4.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7.06M |
| Avg Daily Volume (30 D): |
.92M |
| Avg Daily Volume (90 D): |
1.19M |
| Trade Size |
| Avg Trade Size (Sh.): |
713 |
| Avg Trade Size (Sh.) (30 D): |
99 |
| Avg Trade Size (Sh.) (90 D): |
79 |
| Institutional Trades |
| Total Inst.Trades: |
288 |
| Avg Inst. Trade: |
$1.59M |
| Avg Inst. Trade (30 D): |
$2.06M |
| Avg Inst. Trade (90 D): |
$1.69M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.1M |
| Avg Closing Trade (30 D): |
$1.85M |
| Avg Closing Trade (90 D): |
$1.63M |
| Avg Closing Volume: |
39.61K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-3.86
|
$-2.84
|
$-171.94
|
|
Diluted EPS
|
$-3.86
|
$-2.84
|
$-171.94
|
|
Revenue
|
$ 2M
|
$ 2.43M
|
$ 2.58M
|
|
Gross Profit
|
$ -1.27M
|
$ 1.49M
|
$ 1.4M
|
|
Net Income / Loss
|
$ -28.27M
|
$ -16.83M
|
$ -22.11M
|
|
Operating Income / Loss
|
$ -28.3M
|
$ -16.05M
|
$ -22.48M
|
|
Cost of Revenue
|
$ 3.27M
|
$ .94M
|
$ 1.18M
|
|
Net Cash Flow
|
$ -6.38M
|
$ 32.94M
|
$ 70.55M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Feb 05, 2025:
1:100
|
|
Jun 10, 2024:
1:32
|
|
May 10, 2023:
4:25
|
|
May 17, 2022:
1:32
|
|
Nov 01, 2019:
1:10
|
|
Nov 28, 2018:
1:10
|
|
Mar 17, 2017:
1:10
|
|
May 01, 2013:
1:20
|
|
|
|
